Featured Research

from universities, journals, and other organizations

Dosage Appears To Be A Critical Factor In Cocaine Vaccine

Date:
January 29, 2002
Source:
Yale University
Summary:
Dosage appears to be a critical factor in the effectiveness of a cocaine vaccine being tested by Yale researchers that is designed to block the euphoria drug abusers experience.

New Haven, Conn. – Dosage appears to be a critical factor in the effectiveness of a cocaine vaccine being tested by Yale researchers that is designed to block the euphoria drug abusers experience.

Of eight patients in the second phase of clinical trials of the vaccine, one received one dose and the others received three to four doses. Six of the eight patients reported only one or two uses of cocaine during six months of follow up treatment and the two other patients used cocaine on a regular basis during the six months.

"These are very good results for people who abuse cocaine," said Thomas Kosten, M.D., professor of psychiatry at Yale School of Medicine and lead researcher on the project. There are an estimated three million cocaine abusers, making cocaine the second most commonly abused illicit drug after marijuana.

Kosten hopes to enroll a total of 150 patients in the second phase of the trial. The goal in this next stage, which is being conducted on an out patient basis, is to determine the dosage and the degree of addiction.

The first phase of the clinical trial included 34 subjects and was intended to test how the vaccine worked, whether it was safe, and if there were any side effects. Kosten published the results of the Phase One trial in the January issue of the journal Vaccine.

"We found that the vaccine, TA-CD, is safe, made antibodies, and there is no significant toxicity," he said. "The vaccine was well tolerated and had no serious drug-related adverse events, although three subjects at the highest dose experienced brief post injection twitching at the injection site. We’re now trying to get some sense of whether we can increase the frequency of dosing to perhaps five times to see if we can get the level of antibodies even higher."

The 34 subjects enrolled in the Phase One trial were abstinent cocaine abusers who were confined in a residential drug treatment program. Of that number, 27 completed the full course of three monthly injections. Of these, 24 returned for the final scheduled visit after three months. Fifteen of those inoculated were followed for one year.

"Anti-cocaine antibodies were detected after the second injection, peaked at three months, and declined to baseline by one year," Kosten said.

The vaccine works by binding the cocaine to antibodies on entering the bloodstream, preventing uptake of cocaine across the blood-brain barrier and dulling or even obliterating the euphoric rush.

Kosten said the vaccine probably only will be effective for those drug abusers who are motivated to stop using cocaine because someone intent on getting high can override the vaccine’s binding action by taking more cocaine.

Since just a small amount of cocaine stimulates intense craving for more of the substance, leading to a binge, he said the vaccine may be most effective at reducing this priming effect. "The vaccine may be able to prevent a cocaine slip from turning into a full scale binge and relapse to dependence," Kosten said.

The research is funded by the National Institute on Drug Abuse. The vaccine is being developed by Xenova Pharmaceuticals plc, a biopharmaceutical company based in Cambridge, England.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Cite This Page:

Yale University. "Dosage Appears To Be A Critical Factor In Cocaine Vaccine." ScienceDaily. ScienceDaily, 29 January 2002. <www.sciencedaily.com/releases/2002/01/020129073358.htm>.
Yale University. (2002, January 29). Dosage Appears To Be A Critical Factor In Cocaine Vaccine. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2002/01/020129073358.htm
Yale University. "Dosage Appears To Be A Critical Factor In Cocaine Vaccine." ScienceDaily. www.sciencedaily.com/releases/2002/01/020129073358.htm (accessed August 1, 2014).

Share This




More Mind & Brain News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Google (Kind Of) Complies With 'Right To Be Forgotten Law'

Google (Kind Of) Complies With 'Right To Be Forgotten Law'

Newsy (July 31, 2014) Google says it is following Europe's new "Right To Be Forgotten Law," which eliminates user information upon request, but only to a certain degree. Video provided by Newsy
Powered by NewsLook.com
Stroke Signs: Three Hour Deadline

Stroke Signs: Three Hour Deadline

Ivanhoe (July 31, 2014) Sometimes the signs of a stroke are far from easy to recognize. Learn from one young father’s story on the signs of a stroke. Video provided by Ivanhoe
Powered by NewsLook.com
Grain Brain May Be Harming Us

Grain Brain May Be Harming Us

Ivanhoe (July 31, 2014) Could eating carbohydrates be harmful to our brain health? Find out what one neurologist says about changing our diets. Video provided by Ivanhoe
Powered by NewsLook.com
Playground Tales: Learning to Socialize With Autism

Playground Tales: Learning to Socialize With Autism

Ivanhoe (July 31, 2014) Playgrounds are typically great places where kids can have fun while learning how to interact with other kids, but for some kids with autism, they can have the reverse effect. Hear how researchers are trying to change that. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins